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Abstract 
Background: Many long non coding RNAs have been identified as key modulators in cancer development. A 
lncRNA, DBCCR1-003, derived from the locus of tumor suppressor gene DBCCR1 (deleted in bladder cancer chromo-
some region 1), has unknown function. In the present study, we explored function and molecular mechanism of 
DBCCR1-003 in bladder cancer (BC) development.
Methods: We evaluated the expression levels of DBCCR1-003 in tissues and cells with western blot and quantitative 
real-time polymerase chain reaction. Multiple approaches including chromatin immunoprecipitation assay and RNA 
immunoprecipitation were used to confirm the direct binding of DBCCR1-003 to DNMT1. The recombinant vector 
overexpressing DBCCR1-003 was constructed. Cell proliferation assay, colony formation assay and flow cytometric 
analysis were employed to measure the role of DBCCR1-003 in regulation of cell proliferation, cycle and apoptosis.
Results: Firstly we detected the expression of DBCCR1-003, DBCCR1, DNMT1 (DNA methyltransferase 1) and DNA 
methylation in the promoter of DBCCR1. We found low expression of DBCCR1-003, same as DBCCR1, while high 
expression of DNMT1 and hypermethylation of DBCCR1 gene promoter in BC tissues and T24 cells line. Further stud-
ies revealed that treatment of DNMT inhibitor, 5-aza-2-deoxycytidine(DAC), or overexpression of DBCCR1-003 led to 
increased DBCCR1 expression by reversion of promoter hypermethylation and DNMT1 binding to DBCCR1 promoter 
in T24 cells. Importantly, RNA immunoprecipitation (RIP) showed that DBCCR1-003 physically associates with DNMT1. 
The binding of them was increased with the inhibition of DBCCR1 promoter methylation, indicating that DBCCR1-
003 may bind to DNMT1 and prevent DNMT1-mediated the methylation of DBCCR1. Furthermore, overexpression of 
DBCCR1-003 resulted in significant inhibition of T24 cells growth through the inducing G0/G1 arrest and apoptosis.
Conclusions: Taken together, these findings demonstrated that a novel tumor suppressor DBCCR1-003 regulates 
the expression of DBCCR1 via binding to DNMT1 and preventing DNMT1-mediated the methylation of DBCCR1 in BC. 
LncRNA DBCCR1-003 may serve as a novel biomarker and therapeutic target for BC in future cancer clinic.
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Background
Bladder cancer is the most common cancer of uri-
nary system in china. Although approximately 70  % of 
patients will preliminary diagnosis as nonmuscle-invasive 
BC (NMIBC), 50–70 % of patients will recur and about 
10–20 % will progressed to muscle-invasive BC (MIBC) 
[1]. So, exploring the early diagnostic and prognostic 
markers for bladder cancer and molecular mechanisms 
involving in bladder cancer is significant for raising the 
survival rates of bladder cancer patients. Nowadays, 
many mechanisms involving in bladder cancer have been 
confirm by studies, such as the activation of proto-onco-
gene, the inactivation of tumor suppressor gene (point 
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mutation, rearrangement and deficiency), chromosome 
abnormality and so on. Since many mechanisms are still 
unclear, there is a need to further understand the molec-
ular mechanisms involving in bladder cancer develop-
ment for exploring the effective therapeutic modalities 
and early detection approach.
The long non-coding RNA (lncRNA) is a kind of RNA 
with size over 200  nt and has no protein-coding capac-
ity [2]. Unlike classical coding genes, which function by 
translated into protein molecules, lncRNAs play a key 
roles in regulation of various biological process in the 
shape of RNA and have exhibited less evolutionary con-
straint [3, 4]. The expression of genes has been revealed to 
be regulated by lncRNAs in kinds of different approaches 
including repression of neighboring (cis) genes, distant 
(trans) via histone modification, and through interaction 
with miRNAs [5–7]. Increasing evidences have indicated 
that lncRNAs were closely involved in carcinogenesis and 
have the potential to be early tumor diagnostic mark-
ers and molecular-targeted therapy sites [5, 8, 9]. In BC, 
lncRNAs are associated with carcinogenesis, develop-
ment and prognosis [10, 11]. Xue et al. found that the low 
expression of lncRNA MDC1-AS was involved in BC by 
up-regulation of its antisense tumor suppressing gene 
MDC1 [12]. He et al. revealed a new lncRNA, linc-UBC1 
(Up-regulated in bladder cancer 1), was over-expressed in 
BC tissues and it was associated with lymph node metas-
tasis and poor survival [13]. Accumulating evidence indi-
cated that abnormal expression of lncRNAs had a close 
relationship with cancers [14, 15]. So, lncRNAs have the 
potential to be diagnostic markers and therapeutic tar-
gets for BC in the clinic.
It is generally accepted that lncRNAs, as any other pro-
tein-coding gene, undergo the same regulatory mecha-
nisms including epigenetic regulation [16, 17]. As one of 
the most extensively studied epigenetic change, Aberrant 
DNA methylation is associated with various biological 
processes including cancer [18–21]. It is a procedure of 
chemical modification which will specifically methyl-
ate the cytosines located 5′ to guanosines in CpG dinu-
cleotides and give rise to 5-methylcytosine (m5C) via the 
DNA methyltransferases (DNMTs) [22]. As one of the 
DNMTs, DNMT1 has the power to maintain the meth-
ylation of newly replicated DNA. Studies have dem-
onstrated that lncRNAs could associate with DNMT1, 
contributing to the expression of gene and aberrant DNA 
methylation during the tumorigenesis [23]. However, 
whether the tumorigenesis and development of BC can 
affected by lncRNAs via DNMT1 or not and the molecu-
lar mechanism involved in the process are unclear.
Lately, studies had identified that lncRNA may directly 
associate with DNMT1 through binding to it, and pre-
vent the methylation of tumor suppressor gene [24]. In 
colon cancer, lncRNA with low expression was also found 
to regulate epigenetic modifications and the expression of 
specific gene by assembles DNMT1 at specific genomic 
sites [25]. To examine if this function be suitable for BC, 
we investigated a well-studied tumor suppressor gene 
DBCCR1 (deleted in bladder cancer chromosome region 
1) with a methylation sensitive and lncRNA DBCCR1-
003 (name got from the database of lncRNAs, transcript 
ID:ENST00000482797) arising from the locus of DBCCR1. 
DBCCR1 is located at chromosome 9q32-33 identified by 
loss of heterozygosity (LOH) studies of human BC to act 
as a tumor suppressor gene [26]. Performing demethyla-
tion experiments in BC cells resulted in the re-expression 
of DBCCR1 mRNA indicating that DBCCR1 expression 
is silenced by hypermethylation [27]. These features make 
DBCCR1 be a good candidate for our study.
To prove our hypothesis, we first test the expression of 
DBCCR1-003, DBCCR1 and DNMT1 as well as meth-
ylation state of DBCCR1 promoter in BC cells and tis-
sues. Then, we investigated the expression change of 
DBCCR1-003, DBCCR1 and DNMT1 and methylation 
dynamics of DBCCR1 by knock-in DBCCR1-003 and 
conducting demethylation treatment in BC cells. The 
function of DBCCR1-003 was determined by using cell 
proliferation, clone formation assay, cell apoptosis and cell 
cycle analysis. RNA immunoprecipitation (RIP) was con-
ducted to confirm if DBCCR1-003 physically associates 
with DNMT1. Chromatin immunoprecipitation (ChIP) 
was performed to measure the binding of DNMT1 in 
DBCCR1 CpG island promoter. According to the research 
conclusions above and our previous results, this study was 
designed to detect that whether the tumorigenesis and 
development of BC can affected by lncRNA DBCCR1-003 
via DNMT1 or not, and investigate the possible underly-
ing molecular mechanism involved in the process.
Methods
Patients and tissue samples
This study has been reviewed by the Institutional Review 
Board (IRB) of Guangzhou Medical University with the 
approval number of GMU-IRB#: 2015-11. After being 
acquainted with the aim and the methods used in the 
study, each of the patients included in the study signed 
a written informed consent form. Between January 2012 
and May 2015, a total of 24 specimens were obtained 
from patients undergoing BC surgery at the first affili-
ated Hospital of Guangzhou medical University (Kangda 
Road 1#, Haizhu District, Guangzhou, Guangdong, 
China). None received any antitumoral treatment prior 
to tumour sampling. All specimens were pathologically 
graded and staged according to the TNM and World 
Health Organization classification. The histopathologi-
cal classification of urinary BC was confirmed by two 
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independent histopathologists. A total of 24 adjacent tis-
sues of cancer from matched patients were collected as 
control group. The patients included 14 males and 10 
females. The median patient age was 69 years with range 
47 to 90 years. More details of characteristics are classi-
fied into Table 1.
Cell culture and transfection
Both of the human urinary bladder transitional car-
cinoma cell lines T24 and human bladder epithelial 
immortalized cell lines SV-HUC-1 were purchased from 
American type culture collection (ATCC). The T24 cells 
was cultured in RPMI 1640, and SV-HUC-1 cells was 
cultured in F12K. All medium were supplemented with 
10  % fetal bovine serum (Gibco, USA), in a humidified 
air atmosphere of 5 % CO2 at 37 °C. We had used 0.25 % 
trypsin (with 1  mM EDTA) (Invitrogen, Carlsbad, CA) 
to harvest the cells for further experiment. Cells were 
grown in polystyrene 25 cm2 dishes and transfected with 
3.0 μg of DNA using 30 μl of Lipofectamine transfection 
reagent (Life Technologies) according to the manufactur-
er’s recommendations for 6 h.
Construction of vectors
Plasmid cDNA-DBCCR1-003 was constructed by intro-
ducing SpeI-NotI fragment containing the DBCCR1-003 
cDNA into the same site in LentiORF PLEX-MCS vector. 
The recombinant vectors were designated as LentiORF 
PLEX-MCS-DBCCR1-003 and identified by sequencing. 
At the same time, we also constructed the control vector 
named PLEX-MCS-control. Both of the vectors were trans-
fected in 293FT cells, respectively. Generated virus par-
ticles subsequently infected T24 cells, the positive clones 
were obtained following puromycin selection. The stable 
cell lines achieved were correspondingly designated as 
Lenti-DBCCR1-003(L-D3) and control Lenti-vector (L-C).
Real‑time quantitative PCR
Total RNA was extracted using the Trizol Reagent (Invit-
rogen, USA) according to the instructions. The RNA purity 
and concentration were determined by the UV spectro-
photometer. cDNA was reversibly transcribed from the 
extracted total RNA using an MMLV reagent kit (TaKaRa, 
Japan) and the primers were designed as Additional file 1: 
Table S1. The expression of the filtered lncRNAs and their 
associated encoding genes was measured using SYBR real-
time PCR (qPCR) (Takara Bio, Otsu, Japan) according to 
the manufacturer’s instructions. PCR was then carried out 
as follows: denaturing at 95 °C for 20 s, 40 cycles of 10 s at 
95 °C, 20 s at 58 °C and 30 s at 72 °C.
5‑Aza‑2′‑deoxycytidine (DAC) treatment
T24 cells were seeded at 50  % confluence 6  h before 
treatment. The doses of DAC (Sigma, St Louis, MO) for 
Table 1 Clinicopathologic features of BC patients and the levels of DBCCR1-003 and DNMT1 expression in the cancer tis-
sues
* Significant difference
a Evaluated with the Mann–Whitney U-test
b Evaluated with the Kruskal–Wallis test
c Levels of DBCCR1-003 expression were determined by qRT–PCR assay, and normalized to the U6 levels using the 2−△CT△CT method
d Levels of DNMT1 expression were determined by qRT–PCR assay, and normalized to the GAPDH levels using the 2−△CT△CT method
Characteristic Number of patients Molecular expression level
DBCCR1‑003c p value DNMT1d p value
All patients 24 (100 %)
Gendera 0.403 0.639
 Females 10 (41.6 %) 4.61 (1.10–4.19) 1.68 (1.2–2.39)
 Males 14 (58.4 %) 1.60 (0.56–3.70) 1.87 (0.65–3.43)
Age at diagnosisa 0.887 0.931
 ≤70 years 12 (50.0 %) 2.0 (0.58–3.70) 1.85 (0.65–3.43)
 >70 years 12 (50.0 %) 1.91 (0.56–4.19) 1.74 (0.97–2.39)
Pathologic gradea 0.02* 0.035*
 Low grade 8 (33.3 %) 2.90 (1.39–4.19) 1.4 (0.97–2.19)
 High grade 16 (66.7 %) 1.39 (0.57–2.81) 1.98 (1.15–3.43)
Pathologic stageb 0.14 0.037*
 pTa 5 (20.8 %) 3.39 (2.51–4.19) 1.26 (0.65–1.84)
 pT1 13 (54.2 %) 1.84 (0.66–3.70) 1.74 (1.0–2.39)
 ≥pT2 6 (25.0 %) 1.02 (0.57–1.57) 2.34 (1.35–2.71)
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T24 cells were 12.5 μmol/l. The cell was treated with the 
designated doses for 48 h, and the confluence of the col-
lected cell was never greater than 80 %.
Western blot analysis
Cultured cells were collected and washed three with 
1  ml of PBS. After cracked with protein lysis buffer 
(50 mM Tris (pH 7.4), 150 mM NaCl, 1 %Triton X-100, 
1  % sodium deoxycholate, 0.1  % SDS, sodium ortho-
vanadate, sodium fluoride, EDTA, leupeptin), cells were 
collected in a centrifuge tube. Cell lysates were cen-
trifuged at 13,000×g for 15  min at 4  °C and insoluble 
debris was discarded. Soluble proteins were subjected 
to 8  % SDS-PAGE, after electrophoresis, the proteins 
were transferred onto PVDF membrane and detected by 
immunolabeling with primary and secondary anti-bod-
ies. In this experiment, we made GAPDH as the internal 
reference. Protein bands were quantified using Chemilu-
minescence with Koda film.
Methylation‑specific PCR (MSP)
Primer sequences for DBCCR1 were list in Additional 
file 1: Table S1. Genomic DNA of tissues were extracted 
from frozen specimens and digested by proteinase K fol-
lowed by standard phenol/chloroform purification and 
ethanol precipitation. Reagents required for the bisulfite 
modification of DNA were supplied in the EZ DNA 
Methylation-Gold Kit (ZYMO RESEARCH). The pro-
cess was performed according to the manufacturer’s rec-
ommendations. 1 μg of DNA was modified with sodium 
bisulfite to convert all unmethylated (but not methylated) 
cytosine to uracil followed by amplification with primers 
specific for methylated versus unmethylated DNA [28]. 
DNA from normal lymphocytes was used as control. 
Water was also used as negative control for contamina-
tion. Methylation status of each tumor was evaluated in 
triplicate for reproducible in MSP. PCR products were 
electrophoresed on a 2 % agarose gel for analysis.
Cell proliferation analysis
Cells were plated into a new dish. 1  ×  105 cells were 
plated in triplicate and harvested at the indicated time 
points: 24, 48, 72, and 96  h. The number of cells was 
determined using an Auto T4 Plus Cell Counter (Nexce-
lom Bioscience, USA). Triplicate plates were counted for 
each cell lines.
Colony formation assay
Cell survival was measured using a standard colony 
forming assay. Cells were seeded onto six-well plates at 
400 cells per well. One week later, colonies were fixed 
with 100 % methanol for 15 min and stained with 0.1 % 
crystal violet for 20 min. Microscopic colonies composed 
of more than approximately 50 cells were counted as hav-
ing grown from surviving cells.
Apoptosis determination by flow cytometry
The cells were harvested by centrifugation for 3  min at 
1000  rpm and were resuspended in binding buffer. Ali-
quots containing 1  ×  105 cells in 190  μl of buffer were 
stained with 10 μl of PI solution and with 5 μl of Annexin 
V-FITC (eBioscience, USA) for 10 min at room tempera-
ture. The excitation and emission wavelengths of FITC was 
FL1 PMT with 515–545 nm, and PI was FL3 with 650 nm. 
Then Flow cytometric analysis was performed using a flow 
cytometer (BD, USA) to detect the cell apoptosis.
Cell cycle analysis
Cells were collected by trypsin method, washed with 
PBS, fixed overnight at 4  °C in 70 % ethanol. They were 
then washed in cold PBS and resuspended in 50  μg/ml 
propidium iodide and RNase A (50 μg/ml). The cell sus-
pension was incubated in a 37 °C water bath for 1 h and 
cell cycle distribution was determined by flow cytometry. 
The cell cycle phase quantification was performed using 
ModFit LT to detect the cell apoptosis.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation was performed with 
EZ-Magna ChIP A/G kit (Millipore) according to man-
ufacturer’s instructions. Briefly, protein extract form 
1 × 107 cells were used for each reaction. Proteins were 
cross-linked to DNA by adding formaldehyde to the 
cell culture medium to a final concentration of 1  % at 
room temperature for 10  min and quenched by addi-
tion of 0.125 M glycine for 5 min at room temperature. 
The nucleus was isolated with nuclear lysis buffer (Mil-
lipore) supplemented with protease inhibitor cocktail 
(Millipore). Cells were sonicated and sheared to yield 
fragments between 200 and 1000 bp. 5 μg of either anti-
DNMT1 (Abcam), Normal mouse IgG (the negative con-
trol) and anti-RNA polII (Millipore) (the positive control) 
was added to the sonicated samples and incubated at 4 °C 
overnight with rotation. Immune complexes were col-
lected with Protein A/G agarose beads and washed with 
low salt buffer, high salt buffer, LiCl buffer and TE buffer 
to remove nonspecific binding. Protein/DNA complex 
was reverse cross-linked and DNA was purified using 
spin columns. Purified DNA was detected with quanti-
tative PCR. Primers for ChIP-qPCR were listed in Addi-
tional file 1: Table S1.
RNA immunoprecipitation (RIP) assay
RIP was conducted as described in [49]. Briefly, 1 × 107 
cells were harvested and lysed in complete RIP lysis 
buffer. Resuspended nuclear fraction was sheared by a 
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homogenizer and sonicated. Antibodies against DNMT1 
(Abcam) and IgG (Sigma-Aldrich) were incubated with 
magnetic beads (Protein A or G) for 1 h and the nuclear 
lysates were incubated overnight with rotation. Sam-
ples were incubated with Proteinase K and dealed with 
QIAamp MinElut Virus Spin kit (QIAGEN, GER) to iso-
lated RNA. Purified RNA was reverse transcribed into 
cDNA by random primer (GeneCopoeia, USA), and 
detected with quantitative PCR. The binding of ecCEBPA 
and DNMT1 which had been identified by studies was 
used as a positive control [24], and normal mouse IgG 
was used as a negative control. Primers for RIP-qPCR 
were listed in Additional file 1: Table S1.
Statistical analysis
All quantified data were analyzed by the SPSS 13 statis-
tical software. Statistical significance was measured by 
Student’s t test and Mann–Whitney U-test. The relation-
ship between the expression level of DBCCR1-003 and 
clinicopathologic parameters were analyzed using the 
Mann–Whitney U-test when comparing the differences 
between two groups, and using the Kruskal–Wallis test 
when comparing the differences among three or more 
groups. All p values <0.05 were considered significant.
Results
DBCCR1 and DBCCR1‑003 are down‑regulated in BC cells 
and tumor tissues
To determine a lncRNA regulates BC by mediating the 
expression of tumor suppressor gene via DNA methyla-
tion, we firstly chosen and tested three tumor suppres-
sor genes: RASSF1A, RUNX3 and DBCCR1. All of them 
were down-regulated by the hypermethylation of pro-
moter region in BC [26, 29, 30]. The expression level and 
methylation status of these genes in T24 cells and SV-
HUC-1 cells were determined by SYBR real-time PCR 
and MSP, respectively. The results showed that DBCCR1 
and RUNX3 were hypermethylation with a relative low 
expression in T24 cells compared to SV-HUC-1 cells, 
whereas RASSF1A was hypermethylation with a rela-
tive high expression (Fig.  1a, b). Then, by searching the 
database of Ensembl (http://asia.ensembl.org/index.
html), we found non-coding RNAs from the transcripts 
of RASSF1A, RUNX3 and DBCCR1 and analyzed the 
homology between them and their sources via BLAST, 
finally selecting three non-coding RNAs with specific 
sequences: RASSF1A-011, RUNX3-003 (Additional file 1: 
Fig. S1) and DBCCR1-003 (Fig. 1c). Similar to their cor-
responding tumor suppressor genes, the expression level 
of RUNX3-003 and DBCCR1-003 were significantly 
decreased but RASSF1A-011 was increased in T24 cells 
when compared with SV-HUC-1 cells (Fig.  1d). What’s 
more, the expression difference in DBCCR1-003 was 
more obvious. We further measured the expression level 
of DBCCR1 and DBCCR1-003 in 24 pairs of BC tissue 
specimens and matched adjacent tissues of BC. Con-
sistent with the results in cells, DBCCR1 and DBCCR1-
003 had a relatively lower expression in BC tissues when 
compared with the matched adjacent tissues of BC 
(Fig.  1e). Based on the experimental results, we choose 
the DBCCR1-003 as target lncRNA for further studies. 
To analysis the Clinicopathologic features of BC patients, 
we found the lower DBCCR1-003 expression levels was 
significantly correlated with the BC grade, but not patient 
gender, stage and age (Table 1).
DBCCR1‑003 regulates the expression of DBCCR1 via DNA 
hypermethylation
Since the DBCCR1-003 originated from the transcript of 
DBCCR1, both of them were down-regulated in BC cells 
and tissues, suggesting that the expression of DBCCR1 
may be regulated by DBCCR1-003. To prove that, we 
knock-in DBCCR1-003 in T24 cells, generating stable cell 
line Lenti-DBCCR1-003 cells, and tested the expression 
of DBCCR1-003 and DBCCR1 in Lenti-DBCCR1-003 
cells and control counterpart by SYBR real-time PCR. 
The results indicated that the expression levels of 
DBCCR1-003 and DBCCR1 in Lenti-DBCCR1-003 cells 
were higher than those in the mock and Lenti-vector cells 
(Fig. 2a, b). Further study of Western blot analysis showed 
that the results were in line with Real time-PCR (Fig. 2c), 
indicating the expression of DBCCR1 may be regulated 
by DBCCR1-003. Then, as decrease or lost expression of 
methylated gene often caused by DNA hypermethylation 
occurred in carcinogenesis [31], we further hypothesize 
that DBCCR1-003 regulate the expression of DBCCR1 
via DNA methylation. Previously, we found that the 
promoter region of DBCCR1 was hypermethylated in 
T24 cells, but unmethylated in SV-HUC-1 cells by MSP. 
Consistent with the results in cells, 18 out of 24 (75.0 %) 
samples were methylated in BC tissues, while only 5 out 
of 24 (20.8  %) samples were methylated in the matched 
adjacent tissues of BC, suggesting that the methylation 
status of DBCCR1 in BC was statistical significant higher 
than controls (Fig. 2d, e; Additional file 1: Fig. S2). Fur-
thermore, by testing the CpG island promoter methyla-
tion status of DBCCR1 in Lenti-DBCCR1-003 cells and 
control counterpart, we found the methylation level of 
DBCCR1 in Lenti-DBCCR1-003 cells was decreased. 
Additionally, conducting demethylation experiments on 
T24 cells, we found the methylation level of DBCCR1 
was also decreased but the expression of DBCCR1 was 
obviously up-regulated compared to the mock control 
after DAC treatment (Fig. 2b, c, f ). Taken together, these 
results suggest that DBCCR1-003 regulates the expres-
sion of DBCCR1 via DNA hypermethylation.
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Fig. 1 The selection of target lncRNA. a Relative expression of DBCCR1, RUNX3 and RASSF1A in T24 cells compared to SV-HUC-1 cells were meas-
ured by real-time PCR. b The methylation status of DBCCR1, RUNX3 and RASSF1A promoter in T24 cells and SV-HUC-1 cells were measured by MSP. 
U unmethylated status; M methylated status. c Schematic view of lncRNAs DBCCR1-003. The region in black indicates the exon and the region mark-
ing with circular box indicate the specific sequences of lncRNAs DBCCR1-003. d Relative expression of DBCCR1-003, RUNX3-003 and RASSF1A-011 
in T24 cells compared to SV-HUC-1 cells were measured by real-time PCR. e Relative expression levels of DBCCR1 and DBCCR1-003 in 24 pairs of 
bladder cancer tumors (BC) and the matched adjacent tissues of bladder cancer (ATBT) were determined by real-time PCR. Results represent the 
mean + SD from three independent experiments. Asterisk indicate significant difference at p < 0.05
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DNMT1 up‑regulation is responsible for the methylation 
of DBCCR1
Previous studies have demonstrated that DNMT1 over-
expression may play a key role in the hypermethylation of 
gene promoter and is related to the malignant potential 
and poor prognosis of human carcinomatosis [32, 33]. In 
our study, we found that the expression level of DNMT1 
was significant higher in cells and BC tissues (Fig.  3a, 
b). Since we have found that the methylation level of 
DBCCR1 was decreased and the expression of DBCCR1 
was increased in Lenti-DBCCR1-003 cells and T24 cells 
treated with DAC, further studies were conducted to 
determine if DNMT1 was related to the hypermethyla-
tion of DBCCR1. The ChIP assay showed that the bind-
ing of DNMT1 in DBCCR1 CpG island promoter were 
obviously decreased in Lenti-DBCCR1-003 cells and T24 
cells treated with DAC (Fig. 3c). These results indicated 
that DNMT1 up-regulation is responsible for the CpG 
island promoter hypermethylation of DBCCR1.
DBCCR1‑003 may bind to DNMT1 and prevent 
DNMT1‑mediated the methylation of DBCCR1
Contrary to the relationship between the expression of 
DBCCR1-003 and the Clinicopathologic features of BC 
patients, up-regulation level of DNMT1 was found to be 
significantly correlated with the BC grade and stage, but 
not patient gender and age (Table  1). However, Spear-
man’s rank correlation analysis indicated that there was 
no significant negative correlations existed between the 
expression levels of DBCCR1-003 and DNMT1 in BC 
specimens: correlation of DNMT1 with DBCCR1-003 is 
−0.078 (p = 0.717). What’s more, to test the mRNA and 
protein levels of DNMT1 in Lenti-DBCCR1-003 cells and 
T24 cells treated with DAC, Our results indicated that 
DNMT1 expression did not obviously change in Lenti-
DBCCR1-003 cells when compared with control counter-
part (Fig. 4a, b). To determine if DBCCR1-003 physically 
associates with DNMT1 in T24 cells, RIP assay was con-
ducted with specific anti-DNMT1 antibody. The binding 
of ecCEBPA and DNMT1 which had been identified by 
studies was used as a positive control to confirm the suc-
cess of RIP assay. The results indicated that ecCEBPA was 
enriched in the group of DNMT1 compared to the group 
of IgG (Additional file 1: Fig. S3). Similarly, DBCCR1-003 
was detected in the group of DNMT1 and the enrichment 
level was obviously increased in Lenti-DBCCR1-003 
cells, indicating that DBCCR1-003 may physically associ-
ates with DNMT1 in T24 cells (Fig. 4c). Combining with 
the results that both of the methylation of DBCCR1 and 
the binding of DNMT1 in DBCCR1 CpG island promoter 
were decreased in Lenti-DBCCR1-003 cells and T24 
cells treated with DAC, suggesting that DBCCR1-003 
may bind to DNMT1 and prevent DNMT1-mediated the 
methylation of DBCCR1 without affecting the expression 
of DNMT1.
Effects of DBCCR1‑003 on cell growth
In order to clarify whether the expression of DBCCR1-
003 play a significant role in malignant phenotypes, we 
performed cell proliferation and clone formation assay 
to determine the effects of DBCCR1-003 ectopic expres-
sion on cell growth in Lenti-DBCCR1-003 cells and con-
trol counterpart. The results revealed that the growth of 
Lenti-DBCCR1-003 cells was obvious reduced compared 
Fig. 2 DBCCR1-003 regulates the expression of DBCCR1 via DNA hypermethylation. a, b The mRNA expression level of DBCCR1 and DBCCR1-003 in 
Lenti-DBCCR1-003 cells(L-D3) and T24 cells treated by DAC(DAC) compared to the mock and Lenti-vector cells (L-C) were tested by real-time PCR. 
c DBCCR1 protein expression in Lenti-DBCCR1-003 cells and T24 cells treated by DAC compared to the mock and Lenti-vector cells. The intensity 
of protein bands are quantified. 1 MOCK; 2 L-C; 3 L-D3; 4 DAC. d, e MSP analyses of DBCCR1 gene promoter in BC tumor and the matched adjacent 
tissues of BC. f MSP analyses of DBCCR1 gene promoter in Lenti-DBCCR1-003 cells and T24 cells treated by DAC compared to the mock and Lenti-
vector cells. Results represent the mean + SD from three independent experiments. Asterisk indicate significant difference at p < 0.05
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with that of the Lenti-vector cells. The frequency of col-
ony formation of the Lenti-DBCCR1-003 cells was sig-
nificantly lower than that of Lenti-vector cells. Further 
studies in T24 cells treated by DAC and control counter-
part also revealed that cells treated by DAC had signifi-
cantly decreased cell proliferation and a fewer number 
of colonies formed compared with control (Fig.  5a, b). 
These results suggested that up-regulation of DBCCR1-
003 can inhibit cell growth of T24 cells.
Effects of DBCCR1‑003 on apoptosis and cell cycle 
distribution
The high expression of DBCCR1-003 can inhibit cell 
growth in T24 cells, which made us wonder if DBCCR1-
003 can trigger apoptosis in T24 cells. To verify this, 
the effect of DBCCR1-003 on the apoptosis of Lenti-
DBCCR1-003 cells, T24 cells treated by DAC and Lenti-
vector cells were detected by flow cytometry. The results 
indicated that the apoptosis rate of Lenti-DBCCR1-003 
cells was significantly increased in comparison with that 
of the Lenti-vector cells. In accordance with these find-
ings, we also found that the percentages of apoptotic 
cells in T24 cells treated by DAC were as significantly 
increased compared to the Lenti-vector cells. Taken 
together, these results suggest that the up-regulation 
of DBCCR1-003 could induce apoptosis in T24 cells 
(Fig. 6a).
The above findings suggested that DBCCR1-003 plays 
an important role in inhibiting cell growth in T24 cells. In 
order to indentify the possible inhibitory effect mediated 
by DBCCR1-003, the percentage of Lenti-DBCCR1-003 
cells, T24 cells treated by DAC and Lenti-vector cells 
in different cell cycle phases were determined by the 
flow cytometry method. The data showed that Lenti-
DBCCR1-003 cells and T24 cells treated by DAC signifi-
cantly decreased the percentage of cells in S phase and 
increased that in G0/G1 phase compared to Lenti-vector 
cells (Fig. 6b), indicating that up-regulation of DBCCR1-
003 may arrested cell cycle in T24 cells.
Discussion
Nowadays, there have been raising interests in the role of 
lncRNAs in human diseases, especially when it involves 
in the epigenetic modifications. An accumulating number 
Fig. 3 DNMT1 up-regulation is responsible for the methylation of DBCCR1. a Relative expression of DNMT1 in T24 cells compared to SV-HUC-1 
cells was measured by real-time PCR. b Relative expression levels of DNMT1 in 24 pairs of bladder cancer tumors (BC) and the matched adjacent 
tissues of bladder cancer (ATBT) were determined by real-time PCR. c The CHIP analysis of the binding of DNMT1 in DBCCR1 CpG island promoter. 
Quantitative-CHIP analysis was conducted to measure the binding of DNMT1 in DBCCR1 CpG island promoter with specific antibodies of DNMT1 
with normalization by total input DNA. M mark; 1 MOCK;  2 L-C; 3 L-D3; 4 DAC. Results represent the mean + SD from three independent experi-
ments. Asterisk indicate significant difference at p < 0.05
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Fig. 4 DBCCR1-003 may bind to DNMT1 and prevent DNMT1-mediated the methylation of DBCCR1. a, b The mRNA and protein expression level of 
DNMT1 in Lenti-DBCCR1-003 cells (L-D3) and T24 cells treated by DAC (DAC) compared to the mock and Lenti-vector cells (L-C) were tested by real-
time PCR and Western Blot, respectively. c RT-PCR analysis of DBCCR1-003 in RIP with anti-DNMT1. The enrichment of RNA was measured relative to 
the input levels using the 2−△CT method. Relative RNA binding levels of DBCCR1-003 and DNMT1 in Lenti-DBCCR1-003 cells and T24 cells treated 
by DAC compared to the mock and Lenti-vector cells. Results represent the mean + SD from three independent experiments. Asterisk indicate 
significant difference at p < 0.05
Fig. 5 DBCCR1-003 inhibits the growth of T24 cells. a Viable cell number was counted each day for 96 h in Lenti-DBCCR1-003 cells (L-D3) and T24 
cells treated by DAC compared to the mock and Lenti-vector cells (L-C). b The colony numbers was counted after 7 days in Lenti-DBCCR1-003 cells 
and T24 cells treated by DAC compared to the mock and Lenti-vector cells. The data represent the means ± standard deviations (SDs) from three 
independent experiments. The error bars denote the SDs. *p < 0.05
Page 10 of 13Qi et al. Cancer Cell Int  (2016) 16:81 
of studies identified that the epigenetic dysregulation 
of lncRNAs expression in cancer play a key role [7, 17]. 
In this study, our results indicate that down-regulation 
of DBCCR1-003 in BC is responsible for the down-reg-
ulation of DBCCR1 via DNMT1, and overexpression of 
DBCCR1-003 can inhibit cell growth by inducing apop-
tosis and arresting the cell cycle in phase in T24 cells, 
revealing a new lncRNA DBCCR1-003 which can affect 
the tumorigenesis and development of BC by mediating 
tumor suppress gene DBCCR1 via DNMT1.
LncRNAs belong to a versatile group of RNA tran-
scripts without protein-coding potential that function 
via diverse mechanisms and act as regulator in important 
biological processes [34]. Taking into account the wide-
spread function that lncRNAs act in cellular networks, 
there is no surprising that lncRNAs have been involved 
in human diseases, including the cancer [35]. Studies 
have indicated that various lncRNAs are related to cellu-
lar transformation, having the potential to be tumor sup-
pressors or oncogenes, and leading to tumorigenesis [36]. 
In gastric cancer, a newly identified lncRNA, CARLo-5, 
was found to be up-regulated and its knock-down sig-
nificantly inhibited the cell proliferation [37]. Mater-
nally Expressed Gene 3(MEG3), an imprinted gene that 
encodes a lncRNA, lost its expression and was negatively 
associated with tumorigenesis in BC [38]. We found the 
Fig. 6 DBCCR1-003 regulated cell cycle progression and apoptosis in T24 cells. a The bar chart represents the percentage of cells in G0/G1, S, or 
G2/M phase, as indicated. b The percentage of apoptotic cells was determined by flow cytometric analysis. The data represent the mean ± SD from 
three independent experiments. *p < 0.05
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low expression of DBCCR1-003 in T24 cells and BC tis-
sues, and the cell growth of T24 cells was inhibited by 
increasing the expression level of DBCCR1-003, indicat-
ing that DBCCR1-003 plays a key role in inhibiting BC 
growth. To explore the possible mechanism responsible 
for the growth inhibition effect of DBCCR1-003, we per-
formed flow cytometry assay, and found that knock-in 
DBCCR1-003 induced G0/G1 cell-cycle arrest and cell 
apoptosis in T24 cells, indicating that BC cell growth 
mediated by DBCCR1-003 may be related to the regu-
lation of cell cycle and apoptosis. Similar to our results, 
Shi et al. reported that overexpression of lncRNA, BRAF 
activated non-coding RNA(BANCR), would suppress 
colorectal cancer cell growth in vitro and in vivo which 
was related to induction of G0/G1 cell cycle arrest and 
apoptosis by regulating p21 [39]. Ma et al. revealed that 
lncRNA-LET overexpression conferred a inhibition to 
the cell growth of gallbladder cancer cells through pro-
motion of cell cycle arrest at G0/G1 phase and to the 
induction of apoptosis under hypoxic conditions [40]. 
Collectively, our results confirm the tumor-suppressive 
activity of DBCCR1-003 and suggest that overexpression 
of DBCCR1-003 inhibits BC growth through the induc-
ing G0/G1 arrest and apoptosis.
In gallbladder cancer, the down-regulation of lncRNA-
LET was observed to be associated with poor prognosis, 
higher tumor status, nodal status, and clinical stage [41]. 
The similar result was also found in colorectal cancer 
that lower expression of lncRNA BANCR was related 
to increased tumor sizes [41]. To DNMT1, DNA hyper-
methylation on CpG islands is related to the overexpres-
sion of DNMT1 in multistage of BC [42]. Consistent with 
these studies, our results demonstrated that there is the 
down-regulation of DBCCR1-003 and up-regulation of 
DNMT1 is related to BC grade and stage.
It has been identified that the dysregulation of lncR-
NAs is associated with cancer epigenetics [42]. Besides 
the known and possible epigenetic mechanisms that the 
lncRNAs involved in cancer can act on tumor suppres-
sor genes, they may associate with a DNA methyltrans-
ferase and recruit it to the promoter region of a tumor 
suppressor gene, leading to the transcriptional silencing 
of the latter [43]. For example, Li et  al. revealed that a 
lncRNA named AS1DHRS4 (antisense 1 dehydrogenase/
reductase SDR family member 4), transcribed from the 
locus of the DHRS4 gene known to be involved in can-
cer, modulated the expression of DHRS4 by epigenetic 
regulation at the DHRS4L2 promoter region [44]. Based 
on these facts, we hypothesizes that DBCCR1-003 may 
act as a tumor suppressor gene through regulating the 
expression of DBCCR1 via DNA methylation. To prove 
that, we first determined the expression and methylation 
status of DBCCR1 and found that, like the DBCCR1-003, 
it was down-regulated and hypermethylation in T24 cells 
and BC tissues. Then, we knock-in DBCCR1-003 in T24 
cells and found that the expression of DBCCR1 was also 
increased whereas the methylation level of DBCCR1 was 
decreased. Moreover, treating with DAC in T24 cells, 
DBCCR1 was up-regulated while the methylation level 
of DBCCR1’s CpG island was decreased. Meanwhile, 
similar to the effect of knock-in DBCCR1-003, the cells 
growth was inhibited and G0/G1 cell-cycle arrest and cell 
apoptosis was induced in T24 cells treated with DAC. 
Taken together, these results suggest that DBCCR1-003 
may act as a tumor suppressor gene through regulating 
the expression of DBCCR1 via DNA methylation.
Epigenetic dysregulation of cellular genes is an impor-
tant feature in the development of human malignancy. 
More and more evidence has suggested that DNA 
methylation is among the key players in the human uri-
nary system tumors. The DNA methylation is catalyzed 
by DNMTs. As one of the three main types of DNMTs 
(DNMT1,DNMT3A, and DNMT3B)involved in genomic 
DNA methylation, DNMT1 displays a obvious favour for 
hemimethylated over unmethylated DNA and maintains 
DNA methylation [45]. Deepika Dhawan and his cowork-
ers have found that DNMT1 has excellent potential as a 
target for invasive urothelial carcinoma therapy in human 
being [46]. The high expression of DNMT1 was demon-
strated to play a key role in cell transformation in vitro, 
suggesting that the abnormal expression of DNMT1 
may have influence to the development of human can-
cer [47]. In our study, we found that the upregulation 
of DNMT1 expression in T24 cells and BC tissues was 
related to DBCCR1 low expression with hypermethyla-
tion of DBCCR1 promoter. The upregulation of DBCCR1 
expression is associated with a decrease of DNA meth-
ylation of DBCCR1. Intriguingly, the ChIP assay also 
identified that the binding of DNMT1 in DBCCR1 CpG 
island promoter were obviously decreased. These results 
suggested that DNMT1 up-regulation is responsible for 
the hypermethylation of DBCCR1. In addition, Wang 
et al. identified that a novel lncRNA Dum, which modu-
lated DNA methylation by recruiting Dnmts to specific 
promoter regions, silencing its neighboring gene Dppa2 
[48]. Chalei et  al. reported that multiple genes could be 
modulated by a lncRNA Dum to stay away from their 
site of synthesis through binding to DNMT1 and chang-
ing DNA methylation status [49]. Similar to these stud-
ies, we found the expression of DNMT1 did not change 
when DBCCR1-003 was overexpressed. Performing the 
RIP assay to determine if DBCCR1-003 physically asso-
ciates with DNMT1 in T24 cells, the results indicated 
that DBCCR1-003 may bind to DNMT1 in T24 cells. 
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Collectively, the above studies and our results suggest 
that the expression of DBCCR1 may be regulated by 
DBCCR1-003 via binding to DNMT1 without affect-
ing the expression of DNMT1 and preventing DNMT1-
mediated the methylation of DBCCR1 in BC.
Conclusions
This study provides the first evidence that overexpression 
of lncRNA DBCCR1-003 inhibits BC growth through the 
inducing G0/G1 arrest and apoptosis, and the expres-
sion of DBCCR1 may be regulated by DBCCR1-003 via 
binding to DNMT1 and preventing DNMT1-mediated 
the methylation of DBCCR1. Tumor suppressor lncRNA 
DBCCR1-003 may serve as a novel biomarker and thera-
peutic target for BC in future cancer clinic.
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